Holen Sie sich die Stockscreener-App
292.59
0.54%
1.08
Schlusskurs vom Vortag:
$291.51
Offen:
$296.36
24-Stunden-Volumen:
105.79K
Relative Volume:
0.16
Marktkapitalisierung:
$20.58B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
89.04
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
-0.38%
1M Leistung:
-11.91%
6M Leistung:
-4.41%
1J Leistung:
+10.39%
1-Tages-Spanne:
$292.32
$296.36
1-Wochen-Bereich:
$290.98
$301.22
52-Wochen-Spanne:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
292.50 | 20.51B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
127.05 | 223.39B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
90.47 | 136.67B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.67 | 135.88B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.73 | 126.37B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.04 | 48.39B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Evercore ISI initiates Insulet stock with Outperform rating, $370 price target - Investing.com
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Evercore ISI Starts Insulet Corporation (PODD) at Outperform, 'Leading the Tubeless Revolution in Insulin Delivery - StreetInsider
Assessing Insulet (PODD) Valuation After Recent Share Price Pullback - Yahoo Finance
Insulet Corporation Expands Omnipod®? U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating A More Sustainable Future - marketscreener.com
Insulet expands pod recycling program to all U.S. customers By Investing.com - Investing.com India
4 Medical Device Stocks to Buy for Healthy Returns in 2026 - Yahoo Finance Australia
Insulet expands Pod recycling program nationwide across US - StreetInsider
Insulet (NASDAQ: PODD) opens free Omnipod recycling to all U.S. customers - Stock Titan
Munro Partners Purchases Shares of 14,355 Insulet Corporation $PODD - MarketBeat
Castleark Management LLC Takes Position in Insulet Corporation $PODD - MarketBeat
Engineers Gate Manager LP Acquires 96,272 Shares of Insulet Corporation $PODD - MarketBeat
Bellevue Group AG Cuts Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Purchased by Occudo Quantitative Strategies LP - MarketBeat
Bayesian Capital Management LP Invests $3.90 Million in Insulet Corporation $PODD - MarketBeat
A Look Into Insulet Inc's Price Over Earnings - Benzinga
WINTON GROUP Ltd Has $1.27 Million Holdings in Insulet Corporation $PODD - MarketBeat
418,356 Shares in Insulet Corporation $PODD Purchased by Qube Research & Technologies Ltd - MarketBeat
Ossiam Sells 6,988 Shares of Insulet Corporation $PODD - MarketBeat
(PODD) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Insulet Corporation $PODD Shares Bought by California Public Employees Retirement System - MarketBeat
Here is Why Growth Investors Should Buy Insulet (PODD) Now - sharewise.com
Natixis Acquires Shares of 27,563 Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Bought by First Trust Advisors LP - MarketBeat
Insider Buying: Timothy Stonesifer Acquires Shares of Insulet Co - GuruFocus
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet Corp Director Timothy C. Stonesifer Buys 962 Shares - TradingView
Insulet Insider Bought Shares Worth $299,884, According to a Recent SEC Filing - marketscreener.com
Insulet : Appoints Cristal Downing to Newly Created Role of Chief Corporate Affairs Officer - marketscreener.com
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements - Yahoo Finance
Insulet Corporation $PODD Shares Sold by Brown Advisory Inc. - MarketBeat
Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers - Finviz
Insulet (NASDAQ:PODD) Shareholders YoY Returns Are Lagging the Company's 8.5% Five-year Earnings Growth - 富途牛牛
Federated Hermes Inc. Grows Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Purchased by Jump Financial LLC - MarketBeat
FDA clears Insulet’s Omnipod 5 algorithm enhancements - MSN
Insulet gets FDA clearance for updates to Omnipod 5 automated insulin delivery - MSN
1832 Asset Management L.P. Reduces Stock Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation: Inside the Strategy Driving Its Robust Type 2 Adoption! - Smartkarma
Assessing Insulet’s Valuation After Omnipod Expansion and Recent Share Price Volatility - Yahoo Finance
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
FDA Clearance Of Lower-Target Omnipod 5 Upgrade Could Be A Game Changer For Insulet (PODD) - simplywall.st
Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - marketscreener.com
Marshall Wace LLP Boosts Position in Insulet Corporation $PODD - MarketBeat
Baird Financial Group Inc. Reduces Stock Holdings in Insulet Corporation $PODD - MarketBeat
FDA clears Insulet’s enhanced Omnipod 5 insulin delivery system By Investing.com - Investing.com South Africa
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Here's Why Insulet (PODD) is a Strong Growth Stock - sharewise.com
Insulet stock price target maintained at $379 by TD Cowen on FDA clearance - Investing.com Nigeria
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option - Patient Care Online
FDA OKs Algorithm Updates to Insulet’s Omnipod 5 Insulin Pump - Medical Product Outsourcing
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):